| Similar Articles |
|---|
 |
The Motley Fool
March 11, 2011
Travis Hoium |
KV Pharmaceutical Shares Plunged Temporarily: What You Need to Know Shares of drugmaker KV Pharmaceutical fell as much as 14% in a wild ride that currently has the stock trading flat from yesterday's close.   |
Pharmaceutical Executive
May 1, 2011
Jill Wechsler |
Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
January 4, 2012
Sean Williams |
2012 Preview: K-V Pharmaceuticals Conserving cash will be a primary objective for K-V in 2012. |
The Motley Fool
December 23, 2011
Brian Stoffel |
A No-Good, Really Bad, Awful Year for This Pharmaceutical Company CEO's outrageous pricing guides K-V Pharmaceutical down in 2011. |
Chemistry World
September 30, 2014
Phillip Broadwith |
Lumara splits and sells to AMAG and Perrigo Women's health specialist Lumara is to be split in two and sold to AMAG and consumer healthcare firm Perrigo. |
The Motley Fool
November 15, 2007
Charly Travers |
John Edwards, Frozen Caveman Lawyer Presidential hopeful John Edwards' health-care plans could destroy drug research and development in this country by removing the patent protection on breakthrough drugs. |
The Motley Fool
July 30, 2009
Brian Orelli |
A Little Help From the Enemy Unfortunately, it won't last. AstraZeneca went over a small patent cliff, but its competitors were nice enough to throw it some climbing gear. |
Pharmaceutical Executive
July 3, 2007
Louis A. Morris |
Culture Shock The withdrawal of Vioxx signaled a sea change. Welcome to the Culture of Drug Safety. The FDA is making changes in the way it reviews drug safety. Post-marketing staff has been enlarged 25%, and new, tougher laws are on the way. |
Pharmaceutical Executive
January 1, 2006
Kenneth I. Kaitin |
Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do. |
Pharmaceutical Executive
September 1, 2012
Jill Wechsler |
Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare. |
Pharmaceutical Executive
December 1, 2006
Richard A. Epstein |
FDA vs. the Individual In this excerpt from his important new book Overdose, an ever controversial legal scholar argues that the current system overvalues risk, ignores individual differences, and deprives patients of valuable treatments. |
